SPA17: A Potential Drug Target and Biomarker (G53340)

Target Name: SPA17

NCBI ID: G53340

SPA17

SPA17: A Potential Drug Target and Biomarker

SPA17, short for short for spinal cord-associated protein 17, is a protein that is expressed in the spinal cord and is known for its role in the development and maintenance of spinal cord injuries. The spinal cord is responsible for transmitting signals from the brain to the rest of the body, and spinal cord injuries can have severe and long-lasting effects on mobility, strength, and function. As such, SPA17 has been identified as a potential drug target and biomarker for the development of new treatments for spinal cord injuries.

SPA17 is a transmembrane protein that is expressed in the spinal cord and is involved in the development and maintenance of the spinal cord. It is made up of four distinct chains that are held together by disulfide bonds. SPA17 is expressed in the spinal cord and is involved in the development and maintenance of the spinal cord, including the development of new neurons and the formation of new glial cells.

SPA17 has been shown to play a role in the development of spinal cord injuries. Studies have shown that SPA17 is expressed in the spinal cord and is involved in the development of spinal cord injuries. In addition, SPA17 has been shown to be involved in the regulation of neural stem/progenitor cell (NSC) proliferation and differentiation.

As such, SPA17 has been identified as a potential drug target for the development of new treatments for spinal cord injuries. One approach to identifying potential drug targets is to use a computational tool to predict the structure and function of the protein. This approach has been used to identify potential drug targets for SPA17, including targets for the production of SPA17-derived peptides and for the development of SPA17-targeted antibodies.

Another approach to identifying potential drug targets is to use a database of known proteins that are involved in the development and maintenance of spinal cord injuries. This approach has been used to identify potential drug targets for SPA17, including targets for the production of SPA17-derived antibodies and for the development of SPA17-targeted small molecules.

SPA17 has also been shown to be involved in the regulation of pain perception and neuroinflammation. Studies have shown that SPA17 is involved in the regulation of pain perception and neuroinflammation, including the production of pain-sensitive neurotransmitters such as nitric oxide. This suggests that SPA17 may be a potential target for the development of pain medications.

In addition to its potential as a drug target, SPA17 has also been shown to be a potential biomarker for the diagnosis and outcome of spinal cord injuries. Studies have shown that SPA17 is expressed in the spinal cord and is involved in the development and maintenance of spinal cord injuries. This suggests that SPA17 may be a useful biomarker for the diagnosis and outcome of spinal cord injuries.

In conclusion, SPA17 is a protein that is expressed in the spinal cord and is involved in the development and maintenance of spinal cord injuries. As such, SPA17 has been identified as a potential drug target and biomarker for the development of new treatments for spinal cord injuries. Further research is needed to fully understand the role of SPA17 in the development and maintenance of spinal cord injuries and to develop effective treatments.

Protein Name: Sperm Autoantigenic Protein 17

Functions: Sperm surface zona pellucida binding protein. Helps to bind spermatozoa to the zona pellucida with high affinity. Might function in binding zona pellucida and carbohydrates (By similarity)

The "SPA17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPA17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets